MindRank Announces $52 Million Series B Financing

July 10, 2026 - 09:43

MindRank AI Ltd., a clinical-stage biotechnology company based in Hangzhou, China, has announced the completion of a $52 million Series B financing round. The funding was led by a group of institutional investors, though the company did not disclose specific names in the announcement.

The capital will be used to advance MindRank's AI-native drug research and development engine, as well as its growing pipeline of innovative therapies. A key focus of the investment is the continued development of MDR-001, an oral small-molecule GLP-1 receptor agonist. This candidate is currently in Phase III clinical development in China, targeting conditions related to metabolic disorders.

MindRank positions itself at the intersection of artificial intelligence and biotechnology, aiming to streamline the traditionally lengthy and costly process of drug discovery. By leveraging its proprietary AI platform, the company seeks to identify and optimize drug candidates more efficiently than conventional methods.

The Series B round marks a significant vote of confidence from investors in the company's technology and clinical progress. With the new funds, MindRank plans to accelerate its research programs and expand its pipeline beyond MDR-001, potentially bringing new treatment options to patients in need. The company did not provide a timeline for the next clinical milestones.